Calcium alginate beads as a slow-release system for delivering angiogenic molecules in vivo and in vitro.
A method previously used in this laboratory for entrapment of tumor cells in alginate beads has been extended to provide a slow release delivery system for growth factors with known in vivo angiogenic activity. Protein growth factors were entrapped in alginate beads in amounts sufficient to cause incorporation of 3H-thymidine by COMMA-D cells in vitro, and in vivo neovascularization when injected subcutaneously into Balb/c mice. Entrapment of 125I-labelled growth factors showed that the amount of molecule entrapped in alginate beads may vary with the charge of the molecule. In vitro cell proliferation studies showed that entrapment in alginate beads may provide a slow-release system or a stabilizing environment for the protein. In some cases biological activity of the growth factor in solution was increased by the presence of control alginate beads. When alginate-entrapped growth factors were injected into Balb/c mice, induction of new blood vessels could be monitored qualitatively by macroscopic photography and assessed quantitatively by measuring the pooling of radiolabelled red blood cells at the experimental site. Subcutaneous injection of purified angiogenic factors not entrapped in alginate beads did not cause neovascularization. Diffusion of 125I-labelled growth factors from alginate beads in the animal showed that release in vivo may depend on the charge of the protein molecule. These results indicate that injection of purified molecules entrapped in alginate beads provides an effective localized and slow-release delivery of biologically active molecules. This delivery system may extend the time of effectiveness of biologically active molecules in vivo compared to direct injection without alginate entrapment. The method of entrapment and injection has potential for identifying active factors in tumor-induced angiogenesis and testing new compounds as modulators of neovascularization.
Downs
E C
EC
Schering-Plough Research, Bloomfield, New Jersey 07003.
Robertson
N E
NE
Riss
T L
TL
Plunkett
M L
ML
D000464:Alginates; D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D002460:Cell Line; D003692:Delayed-Action Preparations; D004058:Diffusion; D004815:Epidermal Growth Factor / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000008:administration & dosage* / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000494:pharmacology; D020723:Glucuronic Acid; D006603:Hexuronic Acids; D051379:Mice; D008807:Mice, Inbred BALB C; D008863:Microspheres; D012867:Skin / Q000098:blood supply; D013936:Thymidine / Q000378:metabolism
D000464:Alginates; D043925:Angiogenesis Inducing Agents; D003692:Delayed-Action Preparations; D006603:Hexuronic Acids; D016222:Fibroblast Growth Factor 2; D016220:Fibroblast Growth Factor 1; D004815:Epidermal Growth Factor; D020723:Glucuronic Acid; D013936:Thymidine